Only Available By Prescription
Sign up to get notified if we do in the future.
We guarantee the lowest price on all of our prescription products. If you find your medications cheaper at any other recognized licensed mail order pharmacy, we will not only match their price, we will beat it by 25% of the difference. It is our 125% price match guarantee!
Example: If you find a product on Canada Drugs Direct for $50.00 and find the same product for $40.00 at another mail order pharmacy, we will provide you with a $12.50 discount, bringing your total to $37.50.
To get the discount please make sure to mention the price match to the customer service team when they call to collect payment for your order. Or call toll free at 1-888-904-8467 to place the order through the phone.
Terms & Conditions of Program
A generic drug is a copy of the brand-name drug with the same dosage, safety, strength, quality, consumption method, performance, and intended use. Before generics become available on the market, the generic company must prove it has the same active ingredients as the brand-name drug and works in the same way and in the same amount of time in the body.
The only differences between generics and their brand-name counterparts is that generics are less expensive and may look slightly different (eg. different shape or color), as trademarks laws prevent a generic from looking exactly like the brand-name drug.
Generics are less expensive because generic manufacturers don't have to invest large sums of money to develop a drug. When the brand-name patent expires, generic companies can manufacture a copy of the brand-name and sell it at a substantial discount.
Wezlana (ustekinumab-auub) is a biosimilar to Stelara (ustekinumab), a fully human IgG1? monoclonal antibody that targets the p40 subunit shared by interleukin-12 (IL-12) and interleukin-23 (IL-23). It is indicated for the treatment of moderate to severe plaque psoriasis, active psoriatic arthritis, moderate to severe Crohn’s disease, and moderately to severely active ulcerative colitis in adults. By inhibiting IL-12 and IL-23 signaling, Wezlana disrupts inflammatory pathways implicated in autoimmune disease pathogenesis, leading to reduced inflammation and improved clinical outcomes in targeted conditions.
| F act Table | |
| Formula | C6452H9964N1724O2004S46 |
| License | US FDA (approved 2023) |
| Bioavailability | ~57% (subcutaneous) |
| Legal status | Prescription only (Rx-only) |
| Chemical Name | Ustekinumab-aekn |
| Elimination half-life | 15–45 days |
| Dosage (Strength) | 45 mg/0.5 mL, 90 mg/mL prefilled syringe; also IV formulations |
| Pregnancy | Consult a doctor (limited human data) |
| Brands | Wezlana (biosimilar), Stelara (reference) |
| Protein binding | Not applicable (monoclonal antibody) |
| PubChem CID | 115088638 |
| MedlinePlus | a609019 |
| ChEBI | 133754 |
| ATC code | L04AC05 |
| DrugBank | DB06174 |
| KEGG | D08951 |
| Routes of administration | Subcutaneous, Intravenous |
Wezlana is administered via subcutaneous or intravenous injection depending on the condition and treatment phase.
Injection sites should be rotated, and the solution should be brought to room temperature before administration. Healthcare provider training is recommended for proper administration and monitoring during induction.
Each Wezlana prefilled syringe or vial contains ustekinumab-auub in sterile solution. Available strengths include 45 mg/0.5 mL and 90 mg/mL for subcutaneous use, and 130 mg/26 mL vials for intravenous infusion (to be diluted before use). Inactive ingredients include L-histidine, L-histidine monohydrochloride, polysorbate 80, sucrose, and water for injection.
Wezlana is contraindicated in patients with clinically significant hypersensitivity to ustekinumab or any of the formulation components. Anaphylaxis and angioedema have been reported with ustekinumab products.
Wezlana may increase the risk of infections, including serious bacterial, fungal, and mycobacterial infections. Patients should be evaluated for tuberculosis (TB) before initiation, and those with latent TB should receive appropriate prophylactic therapy. Caution is advised in patients with a history of recurrent infections or underlying conditions that predispose them to infections.
Malignancies have been reported in clinical trials. Nonmelanoma skin cancer has occurred, particularly in patients with a history of PUVA therapy. Use caution in individuals with prior malignancy.
Live vaccines should not be administered during treatment. Immunizations should be updated before starting therapy. Hypersensitivity reactions may occur and require immediate discontinuation.
Common and serious side effects associated with Wezlana include:
Exceptional Customer Service
We pride ourselves on delivering excellent customer service with as much accessibility as possible.
If you have any questions at all, or would like to place an order, you are encouraged to contact us by toll-free
phone 1-888-904-8467 or email info@canadadrugsdirect.com.
Top Safety and Quality
Canada Drugs Direct employs dedicated, professional licensed pharmacists to ensure that each and every order is reviewed before it is dispensed for the safety and health of our customers. At CanadaDrugsDirect.com, your health is our top priority.
Product Reviews